Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite...
Transcript of Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite...
![Page 1: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/1.jpg)
Obesity and T2DM trials
Dr Alexander Miras
Senior Clinical Lecturer
Endocrinology
![Page 2: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/2.jpg)
LOOK AHEAD trial - weight loss for diabetes
Look AHEAD NEJM 2013
“with and without cardiovascular disease”
![Page 3: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/3.jpg)
LOOK AHEAD trial - weight loss for diabetes
Look AHEAD NEJM 2013
• aimed 7% weight loss
• 1200 to 1800 kcal per day
• <30% from fat and
• >15% from protein
• group and individual counselling sessions weekly, then less
• meal-replacement products
• 175 minutes of moderate-intensity physical activity per week
• “toolbox”
![Page 4: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/4.jpg)
Lifestyle intervention in obese T2DM patients
Look AHEAD NEJM 2013
![Page 5: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/5.jpg)
No effect of lifestyle intervention on CV mortality
Look AHEAD NEJM 2013
![Page 6: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/6.jpg)
PREDIMED - CV outcomes
• N=7447
• BMI < 40
• High CV risk (50% had T2DM)
Randomised to:
• control group - low fat diet
• MedDiet + virgin olive oil
• MedDiet + nuts
No weight loss
![Page 7: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/7.jpg)
PREDIMED
Estruch R et al, NEJM 2013
![Page 8: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/8.jpg)
PREDIMED Interventions
MedDiet
• abundant use of free olive oil or
• free mixed nuts (30 g/day)
• fruit, vegetables, legumes and fish
• reduction in total meat consumption
• high (≥2) MUFA/SFA ratio
• homemade sauce with tomato
• avoidance of butter, cream, fast food, sweets, pastries, and sugar-sweetened beverages
• moderate consumption of red wine
![Page 9: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/9.jpg)
30% reduction in cardiovascular morbidity (not mortality)
Estruch R et al, NEJM 2013
![Page 10: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/10.jpg)
PREDIMED (diabetes)
• N=418
• BMI <40
• High CV risk
Randomised to:
• control group - low fat diet
• MedDiet + extra virgin olive oil
• MedDiet + nuts
![Page 11: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/11.jpg)
50% reduction in diabetes incidence in PREDIMED
Jordi Salas-Salvadó et al. Dia Care 2011;34:14-19
![Page 12: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/12.jpg)
GLP-1 receptor agonists for weight loss (no diabetes)
Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
• 500 kcal deficit
• 30% fat
• 20% protein
• 50% carbohydrate
• physical activity 150 minutes per week
• pedometers
• 3-day food diary was dispensed
![Page 13: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/13.jpg)
GLP-1 receptor agonists and body weight
Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
![Page 14: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/14.jpg)
GLP-1 receptor agonists and body weight
Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
![Page 15: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/15.jpg)
Liraglutide and glycaemia
Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
![Page 16: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/16.jpg)
GLP-1 receptor agonists and CV risk factors
Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
![Page 17: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/17.jpg)
SCALE Diabetes - aim for weight loss
Davies et al, JAMA. 2015;314(7):687-699
![Page 18: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/18.jpg)
SCALE Diabetes - lifestyle
Davies et al, JAMA. 2015;314(7):687-699
• <30% from fat
• 20% from protein
• 50% of energy from carbohydrates
• 500-kcal/d deficit
• ≥150 min/wk of brisk walking
![Page 19: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/19.jpg)
SCALE Diabetes results
JAMA. 2015;314(7):687-699
![Page 20: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/20.jpg)
SCALE Diabetes results
JAMA. 2015;314(7):687-699
![Page 21: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/21.jpg)
Marso SP et al. N Engl J Med 2016
Liraglutide for CV events in diabetes
![Page 22: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/22.jpg)
Marso SP et al. N Engl J Med 2016
Liraglutide for CV events in diabetes
![Page 23: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/23.jpg)
Marso SP et al. N Engl J Med 2016.
Primary and Exploratory Outcomes
![Page 24: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/24.jpg)
Marso SP et al. N Engl J Med 2016
Selected Adverse Events Reported during the Trial
![Page 25: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/25.jpg)
• pen contains a fixed ratio of insulin degludec 100 units and liraglutide 1.8mg per mL
• doses can be adjusted by 1 unit of insulin degludec and 0.036 mg of liraglutide
• maximum dose at one time of 50 units of insulin degludec and 1.8 mg of liraglutide The Lancet Diabetes & Endocrinology, Volume 2, Issue 11, 2014, 885–893
GLP-1 and insulin
![Page 26: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/26.jpg)
DPP4i CV data
SAVOR-TIMI EXAMINE TECOS
Title The Saxaglitpin Assessment
of vascular Outcomes
Recorded in Patients with DM
EXamination of
cardiovascular outcomes
with aloglitpiN versus
standard of carE in patients
with T2DM and acute
coronary syndrome
Trial Evaluationg
Cardiovascular Outcomes
With Sitaglitpin
Population age>40, CV disease OR
multiple CV risk factors
(1/4 of pts)
age >18
Acute Coronary Sy
within 15-90 days
age>50
Established CV disease
Sample size 16,492 5,380 14,700
HbA1c range 6.5-12% 6.5-11% 6.5-8%
1o
endpoint
Composite of CV
death, non fatal MI,
nonfatal stroke
Composite of CV
death, non fatal
MI, nonfatal
stroke
Composite of CV death, non
fatal MI, nonfatal stroke, or
unstable angina requiring
hospitalisation
Duration of FU 2.1 yrs 1.5yrs 4yrs
Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and
established cardiovascular disease. Am Heart J. 2013;166(6):983–9
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and car- diovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35
![Page 27: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/27.jpg)
DPP4i CV data
SAVOR-TIMI EXAMINE TECOS
Title The Saxaglitpin Assessment
of vascular Outcomes
Recorded in Patients with DM
EXamination of
cardiovascular outcomes
with aloglitpiN versus
standard of carE in patients
with T2DM and acute
coronary syndrome
Trial Evaluationg
Cardiovascular Outcomes
With Sitaglitpin
Population age>40, CV disease OR
multiple CV risk factors
(1/4 of pts)
age >18
Acute Coronary Sy
within 15-90 days
age>50
Established CV disease
Sample size 16,492 5,380 14,700
HbA1c range 6.5-12% 6.5-11% 6.5-8%
1o
endpoint
Composite of CV
death, non fatal MI,
nonfatal stroke
Composite of CV
death, non fatal
MI, nonfatal
stroke
Composite of CV death, non
fatal MI, nonfatal stroke, or
unstable angina requiring
hospitalisation
Duration of FU 2.1 yrs 1.5yrs 4yrs
Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983–9
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and car- diovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35
No increase or
decrease in the rate
of
ischaemic events,
though the rate of
hospitalization
for heart failure was
increased
![Page 28: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/28.jpg)
DPP4i CV data
SAVOR-TIMI EXAMINE TECOS
Title The Saxaglitpin Assessment
of vascular Outcomes
Recorded in Patients with DM
EXamination of
cardiovascular outcomes
with aloglitpiN versus
standard of carE in patients
with T2DM and acute
coronary syndrome
Trial Evaluationg
Cardiovascular Outcomes
With Sitaglitpin
Population age>40, CV disease OR
multiple CV risk factors
(1/4 of pts)
age >18
Acute Coronary Sy
within 15-90 days
age>50
Established CV disease
Sample size 16,492 5,380 14,700
HbA1c range 6.5-12% 6.5-11% 6.5-8%
1o
endpoint
Composite of CV
death, non fatal MI,
nonfatal stroke
Composite of CV
death, non fatal
MI, nonfatal
stroke
Composite of CV death, non
fatal MI, nonfatal stroke, or
unstable angina requiring
hospitalisation
Duration of FU 2.1 yrs 1.5yrs 4yrs
Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983–9
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and car- diovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35
No increase CV risk
in Type 2 diabetes
patients at high-risk
for major adverse
cardiac events
(MACE) due to a
recent acute
coronary syndrome
![Page 29: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/29.jpg)
Lorcaserin
• 5-HT2C receptor agonist • 0.5% absolute decrease in HbA1c • Improvements in lipids and blood pressure • No increase in the rate of cardiac valvular disease • Side effects: headache, dizziness, dry mouth and nausea • EMEA - marketing application withdrawn May 2013 Rueda Clausen, Nature Reviews Endo, 2013
![Page 30: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/30.jpg)
Phentermine + Topiramate
• Neuropsychiatric side effects • EMEA - rejected October 2012 (CV risk profile, neuropsychiatric, teratogenicity) Rueda Clausen, Nature Reviews Endo, 2013
![Page 31: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/31.jpg)
Naltrexone + Bupropion
• Adverse effects include nausea, dry mouth, constipation • Transient rise in BP (~1.5mmHg) • Neuropsychiatric side effects (anxiety, insomnia) • Now approved in USA & EU but requires a new CV outcomes trial
Greenway et al Lancet 2010
![Page 32: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/32.jpg)
Belonarib
• Inhibitor of methionine aminopeptidase 2 (MetAP2)
• Stimulates fat oxidation, lipolysis, reduces appetite
• No lifestyle advice
• Main adverse effect increase in sleep latency, insomnia
• Favourable changes in CV risk factors
• Prader-Willi Syndrome & hypothalamic obesity DOM 2015
![Page 33: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/33.jpg)
EMPAREG - Design
• Randomized, double-blind, placebo-controlled trial • once-daily empagliflozin versus placebo • cardiovascular events in adults with type 2 diabetes • at high cardiovascular risk
• Patients were treated at 590 sites in 42 countries
• Trial continued until an adjudicated primary outcome
event had occurred in at least 691 patients
![Page 34: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/34.jpg)
Participants
• BMI < 45
• eGFR >30
• established cardiovascular disease
• no glucose-lowering agents for at least 12 weeks and HbA1c 7-9% or
• stable glucose-lowering and HbA1c 7-10%
![Page 35: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/35.jpg)
Intervention
• 2-week, open-label, placebo run-in period in which background glucose- lowering therapy was unchanged
• Randomisation 1:1:1 ratio stratified according to:
• HbA1c
• BMI
• eGFR
• geographic region
• Background glucose-lowering therapy unchanged for 12 weeks
• After week 12 investigators encouraged to adjust therapies at their discretion
![Page 36: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/36.jpg)
Outcomes
• Primary outcome: composite of death from cardiovascular causes, nonfatal
myocardial infarction, or nonfatal stroke
• Secondary outcome: composite of the primary outcome plus hospitalization for unstable angina.
• Adverse events of special interest:
• confirmed hypoglycaemia
• urinary tract infection
• genital infection
• Volume depletion
• acute renal failure
• bone fracture
• Diabetic ketoacidosis
• thromboembolic events
![Page 37: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/37.jpg)
Baseline characteristics
• 7028 patients
• 97.0% of patients completed the study
• 25.4% of patients prematurely discontinued a study drug
• Final vital status was available for 99.2%
• Demographic and clinical characteristics were well balanced
• > 99% of patients had established cardiovascular disease
• patients were well treated
• median duration of treatment 2.6 years
• median observation time 3.1 years
![Page 38: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/38.jpg)
Zinman B et al. N Engl J Med 2015. DOI: 10.1056/NEJMoa1504720
Cardiovascular Outcomes and Death from Any Cause
![Page 39: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/39.jpg)
Zinman B et al. N Engl J Med 2015. DOI: 10.1056/NEJMoa1504720
Secondary outcomes
![Page 40: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/40.jpg)
HbA1c
![Page 41: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/41.jpg)
Weight
![Page 42: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/42.jpg)
Systolic BP
no increase in heart rate
small increases (~5%) in LDL and HDL cholesterol
![Page 43: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/43.jpg)
Microvascular complications
![Page 44: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/44.jpg)
Mechanisms
Multifactorial • arterial stiffness • cardiac function and oxygen demand • cardio-renal effects • reduction in albuminuria • reduction in uric acid • weight • visceral adiposity • blood pressure
• Main effect was on death. Why?
• ? Type 1 DM
![Page 45: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/45.jpg)
Discussion
• Hurray!
• ? class effect
• No differences in MI or strokes
• Difference between doses tiny
• NNT: 39 patients during 3-year period to prevent 1 death
(too good to be true?)
![Page 46: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/46.jpg)
Gastric bypass - It’s five operations in one!
• Laparoscopic
• 1-2 hour procedure
• 2-3 days in-patient
• 25-30% weight loss
• 1:300 Risk of Death
Similar to a cholecystectomy
![Page 47: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/47.jpg)
Adjustable Silastic Gastric Banding
• Adjustable Lap Band
• <1 hr procedure
• 1 day in-patient
• 20% weight loss
• 1:1000 Risk of Death
• High risk of re-operation
• Self-sabotage easier
• Reversible
![Page 48: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/48.jpg)
Vertical sleeve gastrectomy
• Laparoscopic
• 1-2 hour procedure
• 2-3 days in-patient
• 25% weight loss
• 1:300 Risk of Death
• ? 1st choice for very obese
![Page 49: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/49.jpg)
3 year effects of metabolic surgery
Schauer PR et al. N Engl J Med 2014;370:2002-2013
![Page 50: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/50.jpg)
3 year metabolic effects of surgery
Schauer PR et al. N Engl J Med 2014;370:2002-2013
![Page 51: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/51.jpg)
Geltrude Mingrone et al Lancet 2015
5 year effects of metabolic surgery
![Page 52: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/52.jpg)
Geltrude Mingrone et al Lancet 2015
5 year metabolic effects of surgery
![Page 53: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/53.jpg)
SOS - Mortality benefit
Sjostrom NEJM 2007
![Page 54: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/54.jpg)
Bariatric surgery and CV mortality
Sjostrom et al, JAMA 2012, 307 (1) 56-65
![Page 55: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/55.jpg)
Case 1
• 50 year old man
• BMI 40
• T2DM for 4 years on Metformin
• HbA1c 8%, BP 154/97, Cholesterol 6.3
![Page 56: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/56.jpg)
Case 2
• 50 year Asian old man
• BMI 29.8
• T2DM for 8 years on Metformin+Dapa+Lira+Glic
• HbA1c 8%, BP 154/97, Cholesterol 6.3
![Page 57: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/57.jpg)
Case 3
• 50 year old man
• BMI 60
• No T2DM
• BP 120/75, Cholesterol 3.1
• No other comorbidities
![Page 58: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/58.jpg)
Case 4
• 50 year old man
• BMI 40
• Pre-diabetes
• BP 120/75, Cholesterol 3.1
![Page 59: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/59.jpg)
Case 5
• 50 year old man
• BMI 40
• T2DM on basal bolus, HbA1c 11%
• Unstable retinopathy
![Page 60: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/60.jpg)
Imperial College London Steve Bloom Tricia Tan Harvinder Chahal Samantha Scholtz Christina Prechtl Ahmed Ahmed Sanjay Purkayastha Krishna Moorthy University College Dublin Carel W le Roux Sabrina Jackson
Acknowledgements
Florida State University Alan C Spector King’s College London Francesco Rubino Ameet Patel Royce Vincent King Saud University, Ghalia Abdeen University of Wurzburg Florian Seyfried University of Zurich Marco Bueter
![Page 61: Obesity and T2DM trials - Amazon S3 · • Stimulates fat oxidation, lipolysis, reduces appetite • No lifestyle advice • Main adverse effect increase in sleep latency, insomnia](https://reader034.fdocuments.in/reader034/viewer/2022052011/6026a2a0be19d220d638d966/html5/thumbnails/61.jpg)
Definition of cardiovascular disease
• MI >2 months prior to informed consent
• Multi vessel coronary artery disease
• Evidence of single vessel coronary artery disease
• Unstable angina >2 months prior to consent
• History of stroke >2 months prior to consent
• Occlusive peripheral artery disease